- Home
- QSI vs SLN Comparison
QSI vs SLN Comparison
Compare QSI & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- SLN
- Stock Information
- Founded
- QSI 2013
- SLN 1994
- Country
- QSI United States
- SLN United Kingdom
- Employees
- QSI N/A
- SLN N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- SLN Health Care
- Exchange
- QSI Nasdaq
- SLN Nasdaq
- Market Cap
- QSI 334.9M
- SLN 273.9M
- IPO Year
- QSI N/A
- SLN N/A
- Fundamental
- Price
- QSI $1.93
- SLN $6.34
- Analyst Decision
- QSI Strong Buy
- SLN Buy
- Analyst Count
- QSI 3
- SLN 5
- Target Price
- QSI $2.38
- SLN $32.60
- AVG Volume (30 Days)
- QSI 8.0M
- SLN 90.6K
- Earning Date
- QSI 08-05-2025
- SLN 08-14-2025
- Dividend Yield
- QSI N/A
- SLN N/A
- EPS Growth
- QSI N/A
- SLN N/A
- EPS
- QSI N/A
- SLN N/A
- Revenue
- QSI $3,443,000.00
- SLN $27,701,000.00
- Revenue This Year
- QSI $77.57
- SLN N/A
- Revenue Next Year
- QSI $251.34
- SLN N/A
- P/E Ratio
- QSI N/A
- SLN N/A
- Revenue Growth
- QSI 167.94
- SLN N/A
- 52 Week Low
- QSI $0.61
- SLN $1.97
- 52 Week High
- QSI $5.77
- SLN $21.99
- Technical
- Relative Strength Index (RSI)
- QSI 56.01
- SLN 58.73
- Support Level
- QSI $1.68
- SLN $5.76
- Resistance Level
- QSI $1.99
- SLN $6.40
- Average True Range (ATR)
- QSI 0.11
- SLN 0.42
- MACD
- QSI 0.01
- SLN -0.03
- Stochastic Oscillator
- QSI 81.25
- SLN 63.93
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.